10/30/	J104 0.	
01	S. P	

Please type a plus sign (+) inside this box

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## UTILITY **PATENT APPLICATION TRANSMITTAL**

9525 Attorney Docket No. Tanja Ligensa et al. First Inventor IGF-1 Receptor Interacting Proteins

(Only for new nonprovision	al applica	tions under 37 CFR 1.53(b)	) [	Express	Mail La	bel No.	[EL9]	12160	)928	US	_92
APPLICATION ELEMENTS			ADDI	RESS	TO:	Commiss Box Pate	ent App	olicatio	n	JC.8	
See MPEP chapter 600 concerning utility patent application contents.  1.			(if a, a	Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a.							
Continuation Divisional X Continuation-in-part (CIP) of prior application No.: 09/453,195  Prior application information: Examiner J. Andres Group Art Unit. 1646  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.											
The incorporation can only be	Telleu upc	19. CORRESPO									
Customer Number or Bar Co	ode Label	0015				or	c <sub>o</sub>	prrespond	lence ad	ldress below	
Name											
Address City			Tele	State				Zip C Fa			
Country	<u> </u>		ı ele	phone	L			, a.	^		
Name (Print/Type)	F. Aar	on Dubberley		Reg	istration	No. (Att		34)	4100	01 80/2001	-
Cinnotuna	1201	10. cal Willet VI						) ate	10/2	ソリノスリリエ	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Commissioner for Patents BOX PATENT APPLICATION Washington, D.C. 20231 Hoffmann-La Roche Inc. 340 Kingsland Street
Nutley, NJ 07110
Case Docket 9525
October 30, 2001

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventor(s): Tanja Ligensa, Ralf Schumacher, Michael Weidner

### For: IGF-1 RECEPTOR INTERACTING PROTEINS

1. The fee has been calculated as shown below:

CLAIMS				
FOR	NO. FILED	NO. EXTRA	RATE	FEE
TOTAL CLAIMS	14 - 20	0	x \$18	
INDEP. CLAIMS	3 - 3	0	x \$84	
MULTIPLE DEPENDENT CLAIMS PRESENTED			+ \$280	
BASIC FEE				\$740
			TOTAL	\$ 740

Please charge Deposit Account No. 08-2525 in the amount noted above.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

George W. Johnston Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110

Agent for Applicant(s)

F. Aaron Dubberley

(Reg. No. 41001)

115111

NO. 08-2525 OUR ORDER NO. 4.0.3.9

DEPOSIT ACCOUNT

**Certification under 37 CFR 1.10** 

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

EL912160928 US

addressed to:

Commissioner for Patents Washington, D.C. 20231

on October 30, 2001

Date

Marta Swaryczewsky

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Marta Swary Chrisky

Papers Submitted for Case Docket 9525 US: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification, Sequence Listing, Diskette, Statement Under 37 CFR 1.821 or 1.825, Drawings, Information Disclosure Statement with PTO Form 1449

#### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Ligensa et al.

Art Unit:

Examiner:

Case Docket 9525

(CIP of Serial No. 09/453,195, filed December 2, 1999)

For: IGF-1 RECEPTOR INTERACTING PROTEINS

# STATEMENT UNDER 37 CFR §1.821 or §1.825

Nutley, New Jersey 07110 October 30, 2001

Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby certify that:

- X The contents of the paper Sequence Listing and computer readable Sequence Listing submitted herewith are the same. (37 CFR §1.821(f))
- The contents of the paper Sequence Listing and computer readable Sequence Listing submitted herewith are the same. No new matter is included. (37 CFR §1.821(f) & (g))

	Each of the substituted sheets of the paper Sequence Listing submitted herewith is
	supported in the captioned application. No new matter is included. (37 CFR
	§1.825(a))
	The contents of the substitute paper Sequence Listing and substitute computer
	readable Sequence Listing submitted herewith are the same. No new matter is
	included. (37 CFR §1.825(a) & (b))
_	The substitute computer readable Sequence Listing submitted herewith is identical
	to that originally filed. (37 CFR §1.825(d))
	No computer readable Sequence Listing is being submitted herewwith. The content
	of the paper Sequence Listing submitted herewith is identical to the content of the
	compliant computer readable Sequence Listing filed in US Patent
	Application Serial No, filed Applicants request the use
	of the above compliant computer readable Sequence Listing in the instant
	application.

Respectfully submitted,

Agent for Applicant(s)
F. Aaron Dubberley

(Reg. No. 41001) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4387

Telefax: (973) 235-2363

115101